United States Biotechnology & Medical Research

AtaiBeckley Inc (ATAI)

Track

AtaiBeckley Inc. insiders executed six sales totaling over $2 million during the past ninety days. These divestments occurred as the stock price surged 77.7%, reaching near-annual highs. Following a positive earnings report in May, leadership members including directors and officers offloaded shares, reflecting a consistent pattern of planned liquidations amidst significant market appreciation.
Ticker: ATAI Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for AtaiBeckley Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 7 Jul 2026
Value US$2,210,904.37 | Price 348.76 | Shares 26,222 (+15.4%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-09 2026-07-07 PlS Planned sale
2.4
HERSHBERG ROBERT
Non-Executive Director
26,222 +15.4%
348.76
US$2,210,904 		26,222 +15.4% 348.76 US$2,210,904
2026-07-07 2026-07-07 PrS Proposed sale
2.4
ROBERT HERSHBERG

Director

Non-Executive Director
5,932
119.18
US$1,791,872 		5,932 119.18 US$1,791,872
2026-06-29 2026-06-26 S Sale
Kochendoerfer Gerd

Chief Operating Officer

Officer
84,376 -36.8%
463.50
US$1,427,843 		84,376 -36.8% 463.50 US$1,427,843
2026-06-26 2026-06-26 PrS Proposed sale
GERD KOCHENDOERFER

Officer

Officer
50,000
4.58
US$229,000 		50,000 4.58 US$229,000
2026-06-29 2026-06-25 S Sale
0.7
Craig Kevin James

Chief Medical Officer

Officer
42,579 -83.5%
4.51
US$192,031 		42,579 -83.5% 4.51 US$192,031
2026-06-25 2026-06-25 PrS Proposed sale
0.7
KEVIN CRAIG

Officer

Officer
85,158
4.17
US$355,109 		85,158 4.17 US$355,109
2026-04-22 2026-04-20 PlS Planned sale
0.7
Craig Kevin James

Chief Medical Officer

Officer
42,579 -83.5%
5.00
US$212,895 		42,579 -83.5% 5.00 US$212,895
2026-04-20 2026-04-20 PrS Proposed sale
0.7
KEVIN JAMES CRAIG

Officer

Officer
42,579
4.03
US$171,593 		42,579 4.03 US$171,593
2026-03-24 2026-03-20 PlS Planned sale
0.7
Craig Kevin James

Chief Medical Officer

Officer
100,000 -92.2%
3.55
US$355,000 		100,000 -92.2% 3.55 US$355,000
2026-03-20 2026-03-20 PrS Proposed sale
0.7
KEVIN JAMES CRAIG

Officer

Officer
100,000
3.57
US$357,000 		100,000 3.57 US$357,000
2026-03-11 2026-03-11 PrS Proposed sale
2.1
Feilding-Mellen Cosmo

Director

Non-Executive Director
750,000
3.99
US$2,991,525 		750,000 3.99 US$2,991,525
2026-02-26 2026-02-26 PrS Proposed sale
2.1
Feilding-Mellen Cosmo

Director

Non-Executive Director
750,000
4.00
US$3,000,000 		750,000 4.00 US$3,000,000
2026-01-06 2026-01-02 S Sale
2.1
Feilding-Mellen Cosmo
Non-Executive Director
39,594 -0.5%
3.90
US$154,377 		39,594 -0.5% 3.90 US$154,377
2025-08-18 2025-08-14 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
8,675,799 +20.5%
2.19
US$19,000,000 		8,675,799 +20.5% 2.19 US$19,000,000
2025-07-02 2025-07-02 PrS Proposed sale
1.5
SAHIL KIRPEKAR

Officer

Officer
83,332
2.81
US$233,830 		83,332 2.81 US$233,830
2025-07-01 2025-07-01 PrS Proposed sale
1.5
SAHIL KIRPEKAR

Officer

Officer
106,093
2.77
US$294,381 		106,093 2.77 US$294,381
2025-06-04 2025-06-04 PrS Proposed sale
1.5
SAHIL KIRPEKAR

Officer

Officer
80,000
2.48
US$198,408 		80,000 2.48 US$198,408
2025-03-24 2025-03-24 PrS Proposed sale
3.2
FLORIAN BRAND

Officer

Officer
100,000
1.54
US$154,090 		100,000 1.54 US$154,090
2025-03-24 2025-03-24 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
1,800,000 +4.4%
1.40
US$2,520,000 		1,800,000 +4.4% 1.40 US$2,520,000
2025-03-24 2025-03-21 S Sale
1.5
Johnson Anne Nagengast

Chief Financial Officer

Officer
33,545 -19.3%
1.35
US$45,286 		33,545 -19.3% 1.35 US$45,286
2025-03-24 2025-03-21 S Sale
1.5
Kirpekar Sahil

Chief Business Officer

Officer
48,563 -29.6%
1.35
US$65,560 		48,563 -29.6% 1.35 US$65,560
2025-03-24 2025-03-21 S Sale
0.6
Short Glenn Frank

Chief Scientific Officer

Officer
13,161 -23.7%
1.35
US$17,767 		13,161 -23.7% 1.35 US$17,767
2025-03-24 2025-03-21 S Sale
1.8
Rao Srinivas

See Remarks

Officer
75,418 -26.2%
1.35
US$101,814 		75,418 -26.2% 1.35 US$101,814
2025-03-24 2025-03-21 S Sale
0.7
Craig Kevin James

Chief Medical Officer

Officer
11,563 -57.8%
1.35
US$15,610 		11,563 -57.8% 1.35 US$15,610
2025-03-21 2025-03-21 PrS Proposed sale
0.7
Craig Kevin James

Officer

Officer
11,563
1.39
US$16,073 		11,563 1.39 US$16,073
2025-03-21 2025-03-21 PrS Proposed sale
0.6
Short Glenn Frank

Officer

Officer
13,161
1.39
US$18,294 		13,161 1.39 US$18,294
2025-03-21 2025-03-21 PrS Proposed sale
1.5
Johnson Anne Nagengast

Officer

Officer
33,545
1.39
US$46,628 		33,545 1.39 US$46,628
2025-03-21 2025-03-21 PrS Proposed sale
1.8
Rao Srinivas

Officer

Officer
75,418
1.39
US$104,831 		75,418 1.39 US$104,831
2025-03-21 2025-03-21 PrS Proposed sale
1.5
Kirpekar Sahil

Officer

Officer
48,563
1.39
US$67,503 		48,563 1.39 US$67,503
2025-03-20 2025-03-20 PrS Proposed sale
3.2
FLORIAN OLAF BRAND

Officer

Officer
300,000
1.38
US$412,560 		300,000 1.38 US$412,560
2025-03-21 2025-03-19 PrS Proposed sale
3.2
Brand Florian

Former Officer

Officer
184,451
1.39
US$256,387 		184,451 1.39 US$256,387
2025-02-19 2025-02-14 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
10,835,718 +36.5%
2.10
US$22,755,008 		10,835,718 +36.5% 2.10 US$22,755,008
2024-05-20 2024-05-16 S Sale
3.2
Brand Florian

See Remarks

Officer
151,303 -31.5%
1.92
US$290,502 		151,303 -31.5% 1.92 US$290,502
2024-05-03 2024-05-03 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
9,333
2.25
US$20,953 		9,333 2.25 US$20,953
2024-04-08 2024-04-08 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
16,777
2.52
US$42,254 		16,777 2.52 US$42,254
2024-04-05 2024-04-05 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
6,423
2.49
US$15,997 		6,423 2.49 US$15,997
2024-04-04 2024-04-04 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
7,100
2.78
US$19,738 		7,100 2.78 US$19,738
2024-04-04 2024-04-04 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
639
2.47
US$1,577 		639 2.47 US$1,577
2024-04-03 2024-04-03 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
107,046
2.13
US$228,031 		107,046 2.13 US$228,031
2024-04-04 2024-04-02 S Sale
1.5
Kirpekar Sahil

Chief Business Officer

Officer
35,801 -35.8%
1.85
US$66,232 		35,801 -35.8% 1.85 US$66,232
2024-04-04 2024-04-02 S Sale
1.5
Johnson Anne Nagengast

Chief Financial Officer

Officer
27,410 -27.1%
1.85
US$50,708 		27,410 -27.1% 1.85 US$50,708
2024-04-04 2024-04-02 S Sale
1.8
Rao Srinivas

See Remarks

Officer
61,640 -35.2%
1.85
US$114,034 		61,640 -35.2% 1.85 US$114,034
2023-11-20 2023-11-16 B Purchase
3.2
Brand Florian

See Remarks

Officer
20,000 +18.2%
1.16
US$23,120 		20,000 +18.2% 1.16 US$23,120
2023-09-14 2023-09-13 B Purchase
3.2
Brand Florian

See Remarks

Officer
40,000 +57.1%
1.45
US$57,968 		40,000 +57.1% 1.45 US$57,968
2023-03-30 2023-03-29 B Purchase
3.2
Brand Florian

See Remarks

Officer
70,000 +inf%
1.48
US$103,558 		70,000 +inf% 1.48 US$103,558
2023-03-29 2023-03-29 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
1,214,297 +3.9%
1.32
US$1,600,443 		1,214,297 +3.9% 1.32 US$1,600,443
2022-05-02 2022-04-29 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
21,900 +1.2%
4.47
US$97,801 		21,900 +1.2% 4.47 US$97,801
2022-05-02 2022-04-28 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
34,700 +2.0%
4.46
US$154,689 		34,700 +2.0% 4.46 US$154,689
2022-04-28 2022-04-27 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
19,803 +1.1%
4.64
US$91,939 		19,803 +1.1% 4.64 US$91,939
2022-04-28 2022-04-26 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
46,207 +2.8%
4.69
US$216,628 		46,207 +2.8% 4.69 US$216,628
2022-04-26 2022-04-25 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
8,961 +0.5%
4.78
US$42,843 		8,961 +0.5% 4.78 US$42,843
2022-04-26 2022-04-22 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
52,820 +3.3%
4.83
US$254,962 		52,820 +3.3% 4.83 US$254,962
2022-05-03 2022-04-21 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
68,688 +4.4%
4.95
US$340,040 		68,688 +4.4% 4.95 US$340,040
2022-05-03 2022-04-20 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
67,703 +4.6%
5.09
US$344,513 		67,703 +4.6% 5.09 US$344,513
2022-04-20 2022-04-19 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
65,315 +4.6%
5.13
US$334,739 		65,315 +4.6% 5.13 US$334,739
2022-04-20 2022-04-18 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
54,322 +4.0%
5.11
US$277,656 		54,322 +4.0% 5.11 US$277,656
2022-04-18 2022-04-14 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
4,967 +0.4%
5.19
US$25,779 		4,967 +0.4% 5.19 US$25,779
2022-04-14 2022-04-12 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
55,197 +4.3%
4.88
US$269,560 		55,197 +4.3% 4.88 US$269,560
2022-04-12 2022-04-11 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
53,926 +4.3%
4.83
US$260,554 		53,926 +4.3% 4.83 US$260,554
2022-04-12 2022-04-08 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
57,689 +4.9%
4.81
US$277,640 		57,689 +4.9% 4.81 US$277,640
2021-06-24 2021-06-22 B Purchase
Angermayer Christian
Non-Executive Director Large shareholder
700,000 +3.6%
15.00
US$10,500,000 		700,000 +3.6% 15.00 US$10,500,000
2021-06-24 2021-06-22 B Purchase
1.5
WEAVER GREGORY L

Chief Financial Officer

Officer
4,666 +inf%
15.00
US$69,990 		4,666 +inf% 15.00 US$69,990
2021-06-24 2021-06-22 B Purchase
Auerbach Michael
Non-Executive Director
4,666 +0.1%
15.00
US$69,990 		4,666 +0.1% 15.00 US$69,990
Explore more

More insider trading research around AtaiBeckley Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America